We have a unique and comprehensive understanding of the uncertain pathway that life sciences companies must travel in their pursuit of success. With longstanding relationships throughout the industry, we’re able to help our portfolio companies find talent for their teams. Our in-depth knowledge of the drug development process enables our management teams to provide insightful guidance and craft effective clinical and regulatory strategies. We also endeavor to further the life of companies by leveraging our extensive professional network.

Pappas Ventures invests in companies across a wide range of stages, from preclinical companies that are within a year of initiating human clinical trials to companies ready to begin Phase 3 studies.


20

Years Pappas Ventures has invested in the life sciences

4

Number of venture capital funds raised

353M

Amount of capital under management

57

Total companies in our portfolio

100+

Number of investment firms Pappas Ventures has co-invested with

700+

Average number of investment opportunities evaluated each year

3.0B

Aggregate market cap of the three portfolio companies that have gone public since June 2012

4

Number of Phase 3 clinical trials currently underway by our active portfolio companies

160M

Paid by Medtronic to acquire our portfolio company TYRX

20

Number of Phase 2 clinical trials currently underway by our active portfolio companies

126M

Amount raised by Ultragenyx Pharmaceutical (Nasdaq: RARE) in February 2014 IPO

260M

Paid by Shire plc to acquire our portfolio company Lumena Pharmaceuticals

11

Number of Phase 1 clinical trials currently underway by our active portfolio companies

935M

Paid by Daiichi Sankyo to acquire our portfolio company Plexxikon

4

IPOs since June 2012

124

FDA-regulated products discovered or in development by our portfolio companies

13

Number of portfolio companies that have an FDA-approved product on the market

3.1M

Projected number of patients treated in 2013 with medicines, devices or diagnostics developed by our portfolio companies

1.8B

Estimated revenues generated by Pappas Ventures companies in 2012

17

Number of preclinical products currently being developed by our portfolio companies